Acta Medica Iranica 2016. 54(2):85-95.

Study of Silymarin and Vitamin E Protective Effects on Silver Nanoparticle Toxicity on Mice Liver Primary Cell Culture
Firouz Faedmaleki, Farshad H Shirazi, Shahram Ejtemaeimehr, Soghra Anjarani, Amir-Ahmad Salarian, Hamidreza Ahmadi Ashtiani, Hossein Rastegar


Nanotechnology is a most promising field for generating new applications in medicine, although, only few nano products are currently in use for medical purposes. A most prominent nanoproduct is nanosilver. Nano-silver has biological properties which are significant for consumer products, food technology, textiles, and medical applications (e.g. wound care products, implantable medical devices, in diagnosis, drug delivery, and imaging). For their antibacterial activity, silver nanoparticles (Ag NPs) are largely used in various commercially available products. The use of nano-silver is becoming more and more widespread in medicine and related applications, and due to its increasing exposure, toxicological and environmental issues need to be raised. Cytotoxicity induced by silver nanoparticles (AgNPs) and the role that oxidative stress plays in this process were demonstrated in human hepatoma cells AgNPs agglomerated in the cytoplasm and nuclei of treated cells, and they induced intracellular oxidative stress. AgNP reduced ATP content of the cell and caused damage to mitochondria and increased production of reactive oxygen species (ROS) in a dose-dependent manner. Silymarin was known as a hepatoprotective agent that is used in the treatment of hepatic diseases including viral hepatitis, alcoholic liver diseases, Amanita mushroom poisoning, liver cirrhosis, toxic and drug-induced liver diseases. It promotes protein synthesis, helps in regenerating liver tissue, controls inflammation, enhances glucuronidation, and protects against glutathione depletion. Vitamin E is a well-known antioxidant and has hepatoprotective effect in liver diseases. In this study, we investigated the cytotoxic effects of Ag NPs on primary liver cells of mice. Cell viability (cytotoxicity) was examined with MTT assay after primary liver cells of mice exposure to AgNPs at 1, 10, 50, 100, 150, 200, 400 ppm for 24h. AgNPs caused a concentration- dependent decrease of cell viability (IC50 value = 121.7 ppm or µg/ml). Then the hepatoprotective effect of silymarin and vitamin E were experimented on silver nanoparticle toxicity on mice liver primary cell culture. The results showed that silymarin at 600µg/ml and vitamin E at 2500µmol/l have protective effects on silver nanoparticle toxicity on mice liver primary cell culture. Viability percentage of the primary liver cell of the mouse were exposed to silver nanoparticles at 121.7ppm and co-treatment of silymarin, and vitamin E is more than viability percentage of the primary liver cell of the mouse were exposed to silver nanoparticles and silymarin or silver nanoparticles and vitamin E.


Silver nanoparticle; Silymarin; Vitamin E; MTT assay

Full Text:



Gerber C, Lang HP. How the doors to the nano-world were opened. Nat Nanotech 2006;1(1):3-5.

Singh N, Manshian B, Jenkins GJ, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 2009;30(23-24):3891-914.

Ahamed M, Alsalhi MS, Siddiqui MK. Silver nanoparticle applications and human health. Clin Chem Acta 2009;411(23-24):1841-8.

Soohee Kim, Ji Eun Choi, Jinhee Choi, Kyu-Hyuck Chung, Kwangsik Park, Jongheop Yi,Doug-Young Ryu, Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells. Toxicol Vitro 2009;23(6):1076-84.

Chaloupka K, Malam Y, Seifalian Am. Nanosilver as a new generation ofnanoproduct in biomedical applications. Trends Biotechnol 2010;28(1):580-8.

Woodrow Wilson International Center for Scholars. A nanotechnology consumer products inventory (2007) Available

Arora S, Jain J, Rajwade JM, et al. Interactions of silver nanoparticles with primary mouse fibroblasts and liver cells. Toxicol Appl Pharmacol 2009;236(3):310-8.

Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett 2008;176(1):1-12.

Nel A, Xia T, Madler L, et al. Toxic potential of materials at the nanolevel. Science 2006;311(5761):622-7.

Vigneshwaran N, Kathe AA, Varadarajan PV, et al. Functional finishing of cotton fabrics using silver nanoparticles. J Nanosci Nanotechnol 2007;7(6):1893-7.

Lee KS, El-Sayed MA. Gold and silver nanoparticles in sensing and imaging: sensitivity of plasmon response to size, shape, and metal composition. J Phys Chem 2006;110(39):19220-5.

Zanette C, Pelin M, Crosera M, et al. Silver nanoparticles exert a long-lasting antiproliferative effect on human keratinocyte HaCaT cell line. Toxicol In Vitro 2011;25(5):1053-60.

Lee YS, Kim DW, Lee YH, et al. Silver nanoparticles induce apoptosis and G2/Marrest via PKCf-dependent signaling in A549 lung cells. Arch Toxicol 2011;85:1529-40.

Haase A, Tentschert J, Jungnickel H, et al. Toxicity of silver nanoparticles in human macrophages: uptake, intracellular distribution and cellular responses. J Phys 2011;304(1):012030.

Takenaka S, Karg E, Roth C, et al. Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats. Environ Health Perspect 2001;109(Suppl 4):547-51.

Lee HY, Park HK, LeeYM, et al. Apractical procedure for producing silver nanocoated fabric and its antibacterial evaluation for biomedical applications. Chem Commun (Camb) 2007;(28):2959-61.

Kim YS, Kim JS, Cho HS, et al. Twenty eight day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley Rats. Inhal Toxicol 2008;20(6):575-83.

Wallace WE, Keane MJ, Murray DK, et al. Phospholipid lung surfactant and nanoparticle surface toxicity: Lessons from diesel soots and silicate dusts. J Nanopart Res 2007;9(1):23-38.

Ji JH, Jung JH, Kim SS, et al. Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2007;19(10):857-71.

Arora S, Jain J, Rajwade JM, et al. Interactions of silver nanoparticles with primary mouse fibroblasts and liver cells. Toxicol Appl Pharmacol 2009;236(3):310-8.

Colvin VL. The potential environmental impact of engineered nanomaterials.Nat Biotechnol 2003;21(10):1166-70.

Sung JH, Ji JH, Yun JU, et al. Lung function changes in Sprague-Dawley rats after prolonged inhalation exposure to silver nanoparticles. Inhal Toxicol 2008;20(6):567-74. 23. Hussain SM, Hess KL, Gearhart JM, et al. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 2005;19(7):975-83.

Hussain SM, Javorina AK, Schrand AM, et al. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci 2006;92(2):456-63.

Park S, Lee YK, Jung M, et al. Cellular toxicity of various inhalable metal nanoparticles on human alveolar epithelial cells. Inhal Toxicol 2007;19(Suppl 1);59-65.

Braydich-Stolle L, Hussain S, Schlager JJ, et al. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci 2005;88(2):412-9.

Trop M, Novak M, Rodl S, et al. Silvercoated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 2006;60(3):648-52.

(28) Zurlo J, Arterburn LM. Characterization of a primary hepatocyte culture system for toxicological studies. In Vitro Cell Dev Biol 1996;32(4):211-20.

Gazák R, Walterová D, Kren V. Silybin and Silymarin – New and Emerging Applications in Medicine. Curr Med Chem 2007;14(3):315-38.

Fernando A. Crocenzi and Marcelo G. Roma, Silymarin as a New Hepatoprotective Agent in Experimental Cholestasis: New Possibilities for an Ancient Medication. Curr Med Chem 2006;13(9):1055-74.

Crocenzi FA, Sanches Pozzi EJ, Pellegrino JM, et al. Beneficial Effects of Silymarin on Estrogen-Induced Cholestasis in the Rat: A Study In Vivo and in Isolated Hepatocyte Couplets. Hepatology 2001;34(2):329-39.

Rainone F. Milk Thistle. Am Fam Physician 2005;72(7):1285-92.

Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005;12(6):559-67.

Ferenci P, Drapsirs B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients withcirrhosis of the liver. J Hepatol 1989;9(1):105-13.

Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clin Drug Invest 2002;22(1):51-65.

Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. 2006;124(5):491-506.

Karimi G, Vahabzadeh M, Lari P, et al. “Silymarin”, a Promising Pharmacological Agent for Treatment of Diseases. Iran J Basic Med Sci 2011;14(4):308-17.

Křen V, Walterová D. Slybin and silymarin – new effects and applications. Biomed Papers 2005;149(1):29-41.

Ligeret H, Brault A, Vallerand d, ET AL. Antioxidant and mitochondrial protective effects of silibinin in cold preservation–warm reperfusion liver injury. J Ethnopharmacol 2008;115(3):507-14.

Hikino H, Kiso Y, Wagner H, et al. Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Med.1984;50(3):248-50.

Wu YF, Fu SL, Kao CH, et al. Chemopreventive Effect of Silymarin on Liver Pathology in HBV X Protein Transgenic Mice. Cancer Res 2008;68(6):2033-42.

Luper S. A review of plants used in the treatment of liver diseases: Part 1. Altern Med Rev 1998;3(6):410-21.

Hajiani EP, Hashemi SJ. Comparison of therapeutic effects of silymarin and vitamin E in nonalcoholic fatty liverM disease: Results of an open-labele, prospective, randomized study. Jundishapur J Nat Pharmaceut Prod 2009;4(1):8-14.

Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. J Gastroenterol 1998;93(2):139-43.

Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61(14):2035-63.

Vailati A, Aristia L, Sozze E, et al. Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993;64:219-31.

Thakur SK. Silymarin- A hepatoprotective agent. Gastroenterol Today 2002;6:78-82.

Carducci R, Armellino MF, Volpe C, et al. Silibinin and acute poisoning withAmanita phalloides. Minerva Anestesiol 1996;62(5):187-93.

Srivastava S, Srivastava AK, Srivastava S, Patnaik GK,Dhawan BN. Effect of picroliv and silymarin on liver regeneration in rats. Indian J Pharmacol 1994;26(1):19-22.

Schopen RD, Lange OK, Panne C. Searching for a new therapeutic principle. Experience with hepatic therapeutic agent legalon. Medical Welt 1969;20(15):888-93.

Sharma A, Chakraborti KK, Handa SS. Anti hepatotoxic activity of some Indian herbal formulations as compared to silymarin. Fitoterapia 1991;62:229-35.

Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 1990;10(4):275-9.

Ramellini G, Meldolesi J. Liver protection by silymarin: In vitro effect on dissociated rat hepatocytes. Arzneimittelforschung 1976;26(1):69-73.

Campos R, Garrido A, Guerra R, et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 1989;55(5):417-9.

Wang M, Grange LL, Tao J. Hepatoprotective properties of Silybum marianum herbal preparation on ethanolinduced liver damage. Fitoterapia 1996;67:167-71.

Desplaces A, Choppin J, Vogel G. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 1975;25(1):89-96.

Vogel G, Tuchweber B, Trost W. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 1984;73(3):355-62.

Wu CG, Chamuleau RA, Bosch KS. Protective effect of silymarin on rat liver injury induced by ischemia. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64(5):259-63.

Kropacova K, Misurova E, Hakova H. Protective and therapeutic effect of silymarin on the development of latent liver damage. Radiats Biol Radioecol 1998;38(3):411-5.

Kosina P, Kren V, Gebhardt R, et al. Antioxidant properties of silybin glycosides. Phytother Res 2002;16(Suppl 1):S33-9.

Miguez MP, Anundi I, Sainz-Pardo LA, et al. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P4502E1. Chem Biol Interact 1994;91(1):51-63.

Miller AL. Antioxidant flavonoids: Structure, function and clinical usage. Altern Med Rev 1996;1(2):103-11.

Dehmlow C, Eahard J, Goot HD. Inhibition of Kupffer cells as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23(4):749-54.

Salmi HA, Sarna S. Effects of silymarin on chemical, functional and morphological alterations of the liver.A double-blind controlled study. Scand J Gastroenterol 1982;17(4):517-21.

Feher I, Deak G, Muzes G. Liver protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989;130(51):2723-7.

Trinchet IC, Coste T, Levy VG. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol 1989;13(2):120-4.

Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol1989;9(1):105-13.

Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of liver: results of a controlled doubleblind randomized and multicenter trial. J Hepatol 1998;28(4):615-21.

Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develops liver complications? Hepatology 2000;31(2):513-20.

(70) Velussi M, Cernigoi AM, De Monte A, et al. Longterm (12 months) treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997;26(4):871-9.

Silybum marianum (Milk thistle). Alt Med Rev 1999;4(4):272-4.

Jacobs BP, Dennehy C, Ramirez G, et al. Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. Am J Med 2002;113(6):506-15.

Bosisio E, Benelli C, Pirola O, et al. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992;25(2):147-54.

Harrison SA, Torgerson S, Hayashi P. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98(11):2485-90.

Gordon A, Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006;21(1 Pt 2):275-80.

Daryani NE, Mirmomen Sh, Farahvash MJ, et al. Vitamin E in the treatment of patients with nonalcoholic steatohepatitis: a placebo- controlled double- blind study. Gut 2002;51(Suppl III):A15.

Levine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatrics 2000;136(6):734-8.

Harrison SA, Torgerson S, Hayashi P. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98(11):2485-90.

Ersoz G, Gunsar F, Karasu Z, et al. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005;16(3):124-8.

Masini A, Ceccarelli D, Giovannini F, et al. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J Bioenerg Biomembr 2000;32(2):175-82.

Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994;27(2):105-12.

Munter K, Mayer D, Faulstich H. Characterization of a transporting system in rat hepatocytes: studies with competitive and non-competitive inhibitors of phalloidin transport. Biochem Biophys Acta 1986;860:91-8

.Boerth J, Strong KM. The clinical utility of milk thistle (Silybum marianum) in cirrhosis of the liver. J Herb Pharmacother 2002;2(2):11-7.

Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98(11):2485-90.

Feher J, Lang I, Nekam K, et al. In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med 1990;15(2-3):129-34.

Vecera R, Zacharova A, Orolin J, et al. The effect of silymarin on expression of selected ABC transporters in the rat. 2011;56(2):59-62.

Metwally MAA, El-Gellal AM, El-Sawaisi SM. Effects of Silymarin on Lipid Metabolism in Rats. World Appl Sci J 2009;6(12):1634-7.

Dvorˇak Z, Kosina P, Walterova´ D, et al. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cellMprotection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett 2003;137(3):201-12.

Farghali H, Kamenikova L, Hynie S, et al. Silymarin effects of intracellular calcium and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 2000;41(2):231-7.

Davila JC, Lenherr A, Acosta D. Protective effect of flavonoids on drug-induced hepatotoxicity in vitro.Toxicology 1989;57(3):267-86.

Valenzuela A, Barría T, Guerra R, et al. Inhibitory effect

of the flavonoid silymarin on the erythrocyte hemolysis induced by phenhylhydrazine. Biochem Biophys Res Commun 1985;126(2):712-8.

Valenzuela A, Guerra R, Garrido A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med 1987;53(5):402-5.

Shin SH, Ye MK, Kim HS, et al. The effects of nanosilver on the proliferation and cytokine expression by peripheral blood mononuclear cells. Int Immunopharmacol 2007;7(13):1813-8.

Carlson C, Hussain S, Schrand A, et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B 2008;112(43):13608-19.

Basaga H, Poli G, Tekkaya C, et al. Free radical scavenging and antioxidative properties of ‘silibin’ complexes on microsomal lipid. Cell Biochem Funct 1997;15(1):27-33.

Baer-Dubowska W, Szaefer H, Krajka- Kuzniak V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica 1998;28(8):735-43.

Kim DH, Jin YH, Park JB, et al. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull 1994;17(3):443-5.

Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994;48(4):753-9.

Feher J, Lang I, Nekam K, et al. Effect of free radicalscavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Medica Hungarica 1988;45(3-4):265-76.

Varga Z, Czompa A, Kakuk G, et al. Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavonolignans. Phytother Res 2001;15(7):608-12.

Sonnenbichler J, Goldberg M, Hane L, et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers, non-response in hepatoma and other malignant cell lines. Biochem Pharmacol.1986;35(3):538-41.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.